LONDON (July 14, 2015) – World Courier, the global leader in specialty logistics and an AmerisourceBergen company, has been granted Wholesale Distribution Authorisation (WDA) by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA). The WDA is a benchmark certifying the company’s quality systems and processes for storing and distributing pharmaceuticals.
World Courier received the WDA certification following an application process and inspection by MHRA. Designed to ensure patients safely receive their proper medications, the regulation serves as a verification measure to enforce the European Union’s Falsified Medicine Directive. MHRA regulations require WDA for companies that store shipments of pharmaceutical products for longer than 36 hours or have a refrigerated storage facility for pharmaceuticals. The company also met requirements to demonstrate compliance with the European Union’s Good Distribution Practice (GDP), guidelines that regulate the storage and transportation of medicinal products intended for human consumption.
“Becoming one of the first specialty logistics companies to acquire Wholesale Distribution Authorisation in the U.K. is a significant accomplishment for AmerisourceBergen, World Courier and our clients,” said Simon Beaumont, Managing Director for World Courier in the U.K. “As the global leader in specialty logistics, we continuously strive to offer our clients the best possible integrated supply chain services to improve the quality and accountability in the transportation, dispensing and storage of pharmaceutical products. The WDA accreditation recognises these efforts and demonstrates our commitment to a safe, secure and efficient specialty pharmaceutical supply chain.”
With World Courier receiving WDA accreditation, shipments of pharmaceuticals to the company’s U.K. location can be stored in MHRA-approved temperature controlled areas over extended periods of time, such as a weekend. Clients can rely on World Courier to be compliant with the MHRA requirements including equipment, documentation and qualified sub-contractors. Additionally, the supply chain’s security is improved by enhanced security and traceability of the shipments, as per MHRA standards.
The WDA accreditation is one way AmerisourceBergen continues to connect patients to vital treatments when and where they need them. Safe and timely delivery of medication is critical to the success of clinical trials and to patients accessing licensed medicinal products.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
2 Commerce Drive
Cranbury, NJ 08512